Please use this identifier to cite or link to this item: http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/376
Title: T-cell adoptive immunotherapy for acute lymphoblastic leukemia
Authors: Fry, Terry J.
Mackall, Crystal L.
Issue Date: 2013
Publisher: American Society of Hematology
Abstract: Substantial progress has been made in the treatment of precursor B-cell acute lymphoblastic leukemia (B-ALL), but recurrent disease remains a leading cause of death in children due to cancer and outcomes for adults with B-ALL remain poor. Recently, complete clinical responses have been observed in small numbers of patients with B-ALL treated with adoptive immunotherapy using T cells genetically engineered to express chimeric antigen receptors (CARs) targeting CD19, a cell surface molecule present in essentially all cases of B-ALL. Preclinical data suggest that CARs targeting CD22, another antigen present in the majority of B-ALL cases, are similarly potent. Several clinical studies already under way will soon more clearly define the rate of response to this novel therapy in B-ALL. Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.
URI: http://220.231.117.85:8000/handle/DHKTYTHD_123/376
Appears in CollectionsHuyết học = Hematology

Files in This Item:
File Description SizeFormat 
Hematology-2013-Fry-348-53.pdf
  Restricted Access
365.76 kBAdobe PDFThumbnail
 Request Item


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.